Inpharma

Rituximab rallies against MS
pp. 1-1(1)

MACE an unreliable endpoint in cardiovascular studies
pp. 2-2(1)

Primary care must be addressed by US presidential hopefuls
pp. 3-3(1)

Drug-eluting stents: weighing up the pros and cons
pp. 3-3(1)

Flu vax not effective in α1-antitrypsin deficiency
pp. 3-3(1)

Full prescription coverage of value following MI
pp. 3-3(1)

Mass rotavirus vaccination "attractive" in The Netherlands
pp. 4-4(1)

Increased drug spending improves outcomes in industrialised nations
pp. 4-4(1)

Copayments and caps could be creating false economy
pp. 4-4(1)

Willingness-to-pay for dengue vaccine high in the Philippines
pp. 5-5(1)

Rise in 2nd-gen antipsychotic use lowers hospitalisation rate
pp. 5-5(1)

Mycobacterium w vaccine effective against pulmonary TB
pp. 5-5(1)

Administering ipilimumab after GVAX cancer vaccine appears to limit the expected severe inflammatory response
pp. 5-5(1)

News from the ASCO Genitourinary Cancers Symposium
pp. 6-7(2)

Mifamurtide boosts chemo efficacy in osteosarcoma
pp. 7-7(1)

Postamputation pain appears to respond to perineural etanercept injections
pp. 7-7(1)

Intranasal noninhaled CO2 may be effective for the treatment of seasonal allergic rhinitis
pp. 7-7(1)

"DHA-paclitaxel has modest activity as monotherapy in patients with previously untreated advanced oesophago-gastric adenocarcinoma"
pp. 7-7(1)

A topical formulation of miltefosine [TF 002] may be an effective treatment for patients with severe atopic dermatitis
pp. 7-7(1)

Paclitaxel-coated balloon effective for angioplasty of the leg
pp. 8-8(1)

"Ezetimibe appears to ameliorate the decline of renal function after renal transplantation" in patients with hypercholesterolaemia
pp. 8-8(1)

Adding bevacizumab to docetaxel prolongs survival in breast cancer
pp. 8-8(1)

Interleukin-7 may be beneficial for patients with chronic HIV-1 infections who are categorised as "immune non-responders"
pp. 8-8(1)

Broad-spectrum nanoviricide drug candidates have demonstrated efficacy against Ebola virus in initial cell culture studies.
pp. 8-8(1)

Raltegravir sets new BENCHMRK in treatment-resistant HIV
pp. 9-10(2)

Antidepressant use too rare to impact population suicide rates?
pp. 10-10(1)

β-blockers may be comparable to banding ligation for primary prophylaxis in patients with oesophageal varices
pp. 10-10(1)

A prenatal and postnatal regimen of probiotics significantly reduces the likelihood of infants developing atopic dermatitis
pp. 10-10(1)

Antibacterials ineffectual for preventing middle ear effusion
pp. 10-10(1)

Cefoxitin for postpartum infection prevention in HIV+ women
pp. 11-11(1)

Agalsidase alfa is effective for reversing hypertrophic cardiomyopathy associated with Anderson-Fabry disease
pp. 11-11(1)

Biannual mass antibacterial strategy stamps out trachoma
pp. 11-11(1)

A regimen including chemotherapy and immunotherapy is effective for patients with metastatic melanoma
pp. 11-11(1)

Amiodarone and class IC antiarrhythmic drugs (AADs) are comparable for atrial arrhythmia in patients paced for sinus node disease
pp. 11-11(1)

Insulins for T1DM in pregnancy
pp. 12-12(1)

Levothyroxine beneficial post-thyroidectomy
pp. 12-12(1)

Arsenic trioxide is effective and well tolerated in children and adolescents with acute promyelocytic leukaemia
pp. 12-12(1)

Decline in elderly protection from flu doesn't fly
pp. 12-12(1)

Bezafibrate confers significant long-term cardiovascular protection among patients with coronary artery disease
pp. 13-13(1)

Salmeterol/fluticasone propionate effective for mild asthma
pp. 13-13(1)

Gemcitabine is an effective treatment option for patients with nasopharyngeal cancer after failing platinum-based chemotherapy
pp. 13-13(1)

Omalizumab gives real results in `real-life' hard-to-treat asthma
pp. 13-13(1)

Extended-release cyclobenzaprine [Amrix] compares favourably with immediate-release cyclobenzaprine for moderate-to-severe muscle spasm
pp. 13-13(1)

Tegafur/uracil in combination with cisplatin appears to be active in advanced non-small-cell lung cancer
pp. 14-14(1)

Second-line rituximab improves prognosis in B-cell lymphoma
pp. 14-14(1)

Intralesional steroid therapy plus endoluminal surgery appears to be an effective treatment option for airway obstruction due to Wegener's granulomatosis
pp. 14-14(1)

Smoking cessation with bupropion influenced by genetics
pp. 14-14(1)

Induction therapy involving thalidomide improves outcomes in patients with newly-diagnosed multiple myeloma
pp. 14-14(1)

Gemcitabine plus irinotecan appears to be an effective treatment option for previously treated patients with small-cell lung cancer
pp. 14-14(1)

Itraconazole and fluconazole are comparable for the treatment of acute vaginal or vulvovaginal candidiasis in nonpregnant women
pp. 15-15(1)

The `first prospective report' on lopinavir/ritonavir pharmacokinetics, efficacy and safety in young infants with HIV-1 infection shows favourable findings
pp. 15-15(1)

Recombinant erythropoietin therapy may provide survival benefit in patients with myelodysplastic syndromes
pp. 15-15(1)

Tiotropium and ipratropium go head-to-head in COPD
pp. 15-15(1)

Mycophenolate mofetil may slow disease progression in patients with interstitial lung disease secondary to systemic scleroderma
pp. 15-15(1)

Physiologic growth hormone (GH) replacement appears to be beneficial in patients with HIV-associated lipodystrophy
pp. 15-15(1)

Sunitinib appears to be an effective single-agent therapy for patients with recurrent non-small-cell lung cancer
pp. 17-17(1)

Switching from ergot dopamine agonists to pramipexole appears to be effective
pp. 17-17(1)

The BP reduction with ACE inhibitors appears to be greater in patients with a particular genetic polymorphism
pp. 17-17(1)

Rituximab is effective for the treatment of atopic dermatitis
pp. 17-17(1)

To switch patients from epoetin alfa or beta to darbepoetin alfa, the required dose is significantly less than equimolar.
pp. 17-17(1)

The normalisation of B cell counts and subpopulations may explain the antiretroviral therapy (ART)-induced improvement in HIV viraemia
pp. 17-17(1)

The multicentre phase III ESCAPE trial of sorafenib in non-small-cell lung cancer (NSCLC) has been terminated
pp. 17-17(1)

Mirtazapine increases pain tolerance in healthy volunteers
pp. 18-18(1)

With DMARD therapy for rheumatoid arthritis, "no regimen is clearly better than another"
pp. 18-18(1)

Famotidine raises gastric pH earlier than lansoprazole, but the elevation is maintained for a shorter duration
pp. 18-18(1)

Wine consumption is associated with higher levels of protective marine omega-3 fatty acid levels in patients with coronary heart disease
pp. 18-18(1)

Nebivolol may be more beneficial than atenolol for systemic hypertension
pp. 18-18(1)

Clopidogrel adds to aspirin-induced platelet activation, although diabetic patients still exhibit residual platelet activity.
pp. 18-18(1)

Hep B vax not linked to childhood-onset MS
pp. 19-19(1)

Inconclusive findings for aprotinin in paediatric renal impairment
pp. 19-19(1)

Concomitant CYP3A4 inhibitors and calcium channel antagonist therapy is associated with an increased risk of adverse drug reactions
pp. 19-19(1)

A 6-hour oxaliplatin infusion is associated with prevention and reduction of acute neurotoxicity
pp. 19-19(1)

An interim analysis of ADVANCE data provides "no confirmation" of the adverse mortality trend seen in the ACCORD trial
pp. 19-19(1)

News from the ASCO Gastrointestinal Cancers Symposium
pp. 20-20(1)

Corticosteroid administration in the acute phase of cerebral venous thrombosis (CVT) does not improve outcomes
pp. 20-20(1)

Concomitant SSRI and NSAID treatment appears to have a synergistic effect on the risk of upper GI bleeding
pp. 20-20(1)

HAART initiation at CD4 cell counts of ≥ 200 cells/mm3 is associated with a decreased risk of anaemia, renal impairment and peripheral neuropathy
pp. 21-21(1)

Efavirenz has a clinically significant effect on voriconazole pharmacokinetics
pp. 21-21(1)

The perception that gemfibrozil has a less favourable safety profile than fenofibrate may no longer be clinically relevant
pp. 21-21(1)

Neurological adverse effects associated with bevacizumab [Avastin] may arise from damage to brain blood vessels
pp. 21-21(1)

Orthovisc mini [hyaluronic acid] launched in Europe.
pp. 22-22(1)

Once-daily tramadol approved in two new markets.
pp. 22-22(1)

Idursulfase approved in Mexico.
pp. 22-22(1)

AX 200 recommended for orphan drug status in EU.
pp. 22-22(1)

BIBW 2992 has received fast track status in the US
pp. 22-22(1)

Ramipril [Altace] tablets have been launched in the US.
pp. 22-22(1)

Extended-release bupropion approved for SAD in Canada.
pp. 22-22(1)

US FDA document opens door to dissemination of off-label info
pp. 22-22(1)

Levodopa/carbidopa intestinal gel receives fast track designation in US.
pp. 22-22(1)

Lenalidomide [Revlimid] has received orphan drug status in Japan.
pp. 22-22(1)

Generic pramipexole approved by US FDA
pp. 22-22(1)

US orphan drug designation granted for MGCD0103
pp. 23-23(1)

The FDA has approved niacin/simvastatin
pp. 23-23(1)

The US FDA has approved levocetirizine oral solution
pp. 23-23(1)

Zegerid launched in Puerto Rico and the US Virgin Islands.
pp. 23-23(1)